CN110799501A - 一种食欲素受体拮抗剂的晶型及其制备方法和用途 - Google Patents

一种食欲素受体拮抗剂的晶型及其制备方法和用途 Download PDF

Info

Publication number
CN110799501A
CN110799501A CN201880040538.1A CN201880040538A CN110799501A CN 110799501 A CN110799501 A CN 110799501A CN 201880040538 A CN201880040538 A CN 201880040538A CN 110799501 A CN110799501 A CN 110799501A
Authority
CN
China
Prior art keywords
crystal form
solvent
compound
crystalline form
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880040538.1A
Other languages
English (en)
Other versions
CN110799501B (zh
Inventor
陈敏华
张炎锋
黄春香
张晓宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bojian Pharmaceutical Co ltd
Original Assignee
Crystal Pharmaceutical Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65233118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110799501(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crystal Pharmaceutical Suzhou Co Ltd filed Critical Crystal Pharmaceutical Suzhou Co Ltd
Priority to CN202211397034.XA priority Critical patent/CN115710250A/zh
Publication of CN110799501A publication Critical patent/CN110799501A/zh
Application granted granted Critical
Publication of CN110799501B publication Critical patent/CN110799501B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

一种化合物Lemborexant的晶型及其制备方法，含有该晶型的药物组合物，以及该晶型在制备食欲素受体拮抗剂、治疗失眠症和不规则睡眠‑觉醒节律障碍药物制剂中的用途。提供的化合物Lemborexant的晶型比现有技术具有一种或多种改进的特性，对未来该药物的优化和开发具有重要价值。

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN201880040538.1A 2017-08-01 2018-07-31 一种食欲素受体拮抗剂的晶型及其制备方法和用途 Active CN110799501B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211397034.XA CN115710250A (zh) 2017-08-01 2018-07-31 一种食欲素受体拮抗剂的晶型及其制备方法和用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710648135 2017-08-01
CN2017106481352 2017-08-01
PCT/CN2018/097797 WO2019024845A1 (zh) 2017-08-01 2018-07-31 一种食欲素受体拮抗剂的晶型及其制备方法和用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211397034.XA Division CN115710250A (zh) 2017-08-01 2018-07-31 一种食欲素受体拮抗剂的晶型及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN110799501A true CN110799501A (zh) 2020-02-14
CN110799501B CN110799501B (zh) 2022-11-22

Family

ID=65233118

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880040538.1A Active CN110799501B (zh) 2017-08-01 2018-07-31 一种食欲素受体拮抗剂的晶型及其制备方法和用途
CN202211397034.XA Pending CN115710250A (zh) 2017-08-01 2018-07-31 一种食欲素受体拮抗剂的晶型及其制备方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211397034.XA Pending CN115710250A (zh) 2017-08-01 2018-07-31 一种食欲素受体拮抗剂的晶型及其制备方法和用途

Country Status (4)

Country Link
US (1) US10759779B2 (zh)
JP (2) JP7179049B2 (zh)
CN (2) CN110799501B (zh)
WO (1) WO2019024845A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220008804A (ko) * 2019-05-15 2022-01-21 에자이 알앤드디 매니지먼트 가부시키가이샤 오렉신-2 수용체 길항제의 제조에 유용한 방법 및 화합물, 및 약간의 불순물을 갖는 렘보렉산트
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
MX2022002038A (es) * 2019-09-13 2022-03-11 Eisai R&D Man Co Ltd Composicion farmaceutica para el tratamiento del insomnio.
US20240010629A1 (en) 2019-12-11 2024-01-11 Teva Czech Industries S.R.O Solid state form of lemborexant
IL294033A (en) * 2020-01-16 2022-08-01 Eisai R&D Man Co Ltd Medicinal substance of lamborexant and medical preparation containing it

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104114524A (zh) * 2012-02-17 2014-10-22 卫材R&D管理有限公司 用于食欲肽-2受体拮抗剂的合成的方法和化合物
CN104592184A (zh) * 2014-12-15 2015-05-06 云南省药物研究所 灯盏乙素苷元晶型及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020157A (en) * 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) * 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
TWI516484B (zh) * 2010-09-22 2016-01-11 衛材Ｒ＆Ｄ企管股份有限公司 環丙烷化合物
JP6659681B2 (ja) * 2014-10-23 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症を治療するための組成物および方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104114524A (zh) * 2012-02-17 2014-10-22 卫材R&D管理有限公司 用于食欲肽-2受体拮抗剂的合成的方法和化合物
CN104592184A (zh) * 2014-12-15 2015-05-06 云南省药物研究所 灯盏乙素苷元晶型及其制备方法

Also Published As

Publication number Publication date
JP2020528913A (ja) 2020-10-01
US10759779B2 (en) 2020-09-01
CN115710250A (zh) 2023-02-24
US20200190060A1 (en) 2020-06-18
CN110799501B (zh) 2022-11-22
JP7179049B2 (ja) 2022-11-28
WO2019024845A1 (zh) 2019-02-07
JP2023027066A (ja) 2023-03-01

Similar Documents

Publication Publication Date Title
CN110799501B (zh) 一种食欲素受体拮抗剂的晶型及其制备方法和用途
CN111094290B (zh) 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途
CN110088088B (zh) {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
CN111093668A (zh) Gsk1278863 的晶型及其制备方法和制药用途
CN110944982A (zh) 奥扎莫德盐酸盐的晶型及其制备方法
CN113242855A (zh) 他发米帝司的晶型及其制备方法和用途
CN111344283A (zh) Arn-509的晶型及其制备方法和用途
CN112888692A (zh) 一种Upadacitinib的晶型及其制备方法和用途
EP3553058A1 (en) Crystal form of bromodomain protein inhibitor drug, preparation method and use thereof
US20220002306A1 (en) Crystal form of upadacitinib and preparation method and use thereof
EP3733666B1 (en) Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof
CN110799512A (zh) 巴瑞克替尼的晶型及其制备方法
EP4286377A1 (en) Crystal form of resmetirom, preparation method therefor, and use thereof
CN108640910A (zh) 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
CN110291071B (zh) Sb-939的盐的晶型及其制备方法和用途
CN111417624B (zh) Eb-1020的晶型及其制备方法和用途
WO2019105359A1 (zh) Acalabrutinib的晶型及其制备方法和用途
EP4056182A1 (en) Crystal form of aprocitentan, preparation method therefor and use thereof
US20220267326A1 (en) Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
WO2018130226A1 (zh) 利奥西呱的新晶型及其制备方法和用途
CN113015722A (zh) 一种低氧诱导因子脯氨酰羟化酶抑制剂晶型
WO2019011337A1 (zh) Qaw-039的晶型及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210513

Address after: Delaware, USA

Applicant after: Bojian Pharmaceutical Co.,Ltd.

Address before: 215123 Bio-nano Park B4301, No. 218 Xinghu Street, Suzhou Industrial Park, Jiangsu Province

Applicant before: CRYSTAL PHARMACEUTICAL (SUZHOU) Co.,Ltd.

GR01 Patent grant
GR01 Patent grant